Picture of Gilead Sciences logo

GILD Gilead Sciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line4,6445,4605,364896,201
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items9422,1615,2728,4512,760
Unusual Items
Other Non-Cash Items
Changes in Working Capital5,108-939-798-1,638489
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Cash from Operating Activities11,8988,4009,1448,16811,384
Capital Expenditures-590-924-825-650-579
Purchase of Fixed Assets
Other Investing Cash Flow Items-15,47915,279-6,992-13,965-2,552
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-16,06914,355-7,817-14,615-3,131
Financing Cash Flow Items-330-486-122-138-145
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities3,393-12,318-7,634770-8,877
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-64110,352-6,309-5,634-659

Or unlock with your email

Or unlock with your email